Should You Buy Tonix Pharmaceuticals Holding Corp. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Tonix Pharmaceuticals Holding Corp. (TNXP) occupies a solid middle-ground position with a Quality of Company score of 5.9/10. At the current market price of $11.62, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 0 of 1 CirclFi valuation models project upside for Tonix Pharmaceuticals Holding Corp. (TNXP) at $11.62 — the model consensus leans bearish, with a Quality Score of 5.9/10 and Value-Trap risk of 32/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Tonix Pharmaceuticals Holding Corp. (TNXP) in 2026?
What Is the Bull Case vs the Bear Case for Tonix Pharmaceuticals Holding Corp. (TNXP)?
| Bull case | Bear case — $2.96 target (-74.5%) |
|---|---|
| No active model projects meaningful upside for TNXP at $11.62. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $2.96 (-74.5%), suggesting that the market price embeds overly optimistic growth assumptions. |
| Industry headwind: competitive pipeline overlap represents a meaningful risk for Tonix Pharmaceuticals Holding Corp. and its Biotechnology peers. |
How Does TNXP Compare to Its Biotechnology Peers?
Valuation data pages: ATNM · CELZ · NUVB · ABEO · CYTK · RYTM · CELU · PMCB · PBM · EXEL · INCY
Which Other Stocks Score Like TNXP on Quality?
Closest companies to TNXP’s Quality of Company score of 5.9/10, across all industries.
- UAVS — AgEagle Aerial Systems, Inc. (QOC 5.9) · analysis
- PBSV — Pharma-Bio Serv, Inc. (QOC 5.9) · analysis
- FGCO — Financial Gravity Companies, Inc. (QOC 5.9) · analysis
- ZSQR — Z Squared Inc. (QOC 5.9) · analysis
- COMP — Compass, Inc. (QOC 6.0) · analysis
- VELO — Velo3D, Inc. (QOC 5.9) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does TNXP Appear In?
So Is Tonix Pharmaceuticals Holding Corp. (TNXP) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Tonix Pharmaceuticals Holding Corp. at $11.62. 1/1 models flag overvaluation, median fair value sits at $2.96 (-74.5%), and the risk-reward profile appears unfavorable. Quality at 5.9/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Tonix Pharmaceuticals Holding Corp.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About TNXP Stock?
Should I buy TNXP stock right now?
Based on CirclFi's multi-model analysis, 0 of 1 models see upside for TNXP at $11.62. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Tonix Pharmaceuticals Holding Corp.?
Key risks include: limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does TNXP compare to its competitors?
Among Biotechnology peers, TNXP holds a Quality Score of 5.9/10. Comparable companies include ATNM (QOC 6.0), CELZ (QOC 5.9), NUVB (QOC 6.0). The relative ranking helps investors identify whether TNXP offers better fundamental quality than alternatives in the same sector.
Is TNXP a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. TNXP's Quality Score of 5.9/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy TNXP at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $2.96 to $2.96. At $11.62, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for TNXP.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad